|Description||The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.|
|Related CAS||115104-28-4 (free acid)|
|Synonyms||sodium (E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoate; MK-571; MK 571; MK571; MK-571 sodium salt; L-660,711; L660,711; L 660,711; L-660711; L660711; L 660711|
|Solubility||DMSO: ≥ 33 mg/mL|
|Application||The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
ICI-198615 is a novel, potent and selective peptide leukotriene antagonist. It may be useful for the the treatment of allergic diseases.
CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.
HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist. It can inhibit radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC5...
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
This active molecular is a R-enantiomer of MK-571 which is a selective LTD4 receptor antagonist. Verlukast showed [3H]leukotriene D4 binding in guinea-pig with ...
LY-306669, a tetrazol derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied its effect in acute lung injury.
Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of certain natural substances that cau...
This active molecular is an potent dual Leukotriene CysLT1 and CysLT2 Receptor antagonist originated by Ono Pharmaceutical. IC50 values is 1.7nM against human C...
This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...
CP-199330, a chromen derivative, has been found to be a Leukotriene D4 receptor antagonist that was once studied against asthma by Pfizer.
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
Ono-RS-347 is an SRS-A antagonist and a new leukotriene antagonists.
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
CP-195543 is a potent and selective leukotriene B4 antagonist developed as an oral treatment for for inflammatory diseases.
LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
LY 292728, an oxoxanthene derivative, has been found to be a leukotriene B4 receptor antagonist that has once been studied as an antiasthmatic agent.